Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Denali Therapeutics Inc. Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following August 14, 2024 From Denali Therapeutics Inc. Via GlobeNewswire Tickers DNLI Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights August 01, 2024 From Denali Therapeutics Inc. Via GlobeNewswire Tickers DNLI Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies June 03, 2024 From Denali Therapeutics Inc. Via GlobeNewswire Tickers DNLI Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights May 07, 2024 From Denali Therapeutics Inc. Via GlobeNewswire Tickers DNLI Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial May 01, 2024 From Denali Therapeutics Inc. Via GlobeNewswire Tickers DNLI Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights February 27, 2024 From Denali Therapeutics Inc. Via GlobeNewswire Tickers DNLI Denali Therapeutics Announces $500 million Private Placement Equity Financing February 27, 2024 From Denali Therapeutics Inc. Via GlobeNewswire Tickers DNLI Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™ February 07, 2024 From Denali Therapeutics Inc. Via GlobeNewswire Tickers DNLI Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™ February 01, 2024 From Denali Therapeutics Inc. Via GlobeNewswire Tickers DNLI Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases January 08, 2024 From Denali Therapeutics Inc. Via GlobeNewswire Tickers DNLI Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights November 07, 2023 From Denali Therapeutics Inc. Via GlobeNewswire Tickers DNLI Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023 August 30, 2023 From Denali Therapeutics Inc. Via GlobeNewswire Tickers DNLI Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights August 08, 2023 From Denali Therapeutics Inc. Via GlobeNewswire Tickers DNLI Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome) June 20, 2023 From Denali Therapeutics Inc. Via GlobeNewswire Tickers DNLI Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights May 08, 2023 From Denali Therapeutics Inc. Via GlobeNewswire Tickers DNLI Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta April 12, 2023 From Denali Therapeutics Inc. Via GlobeNewswire Tickers BIIB DNLI Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting April 10, 2023 From Denali Therapeutics Inc. Via GlobeNewswire Tickers DNLI Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights February 27, 2023 From Denali Therapeutics Inc. Via GlobeNewswire Tickers DNLI Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™ February 22, 2023 From Denali Therapeutics Inc. Via GlobeNewswire Tickers DNLI Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium™ February 15, 2023 From Denali Therapeutics Inc. Via GlobeNewswire Tickers DNLI Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi January 25, 2023 From Denali Therapeutics Inc. Via GlobeNewswire Tickers DNLI Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases January 09, 2023 From Denali Therapeutics Inc. Via GlobeNewswire Tickers DNLI Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial December 05, 2022 From Denali Therapeutics Inc. Via GlobeNewswire Tickers DNLI Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights November 03, 2022 From Denali Therapeutics Inc. Via GlobeNewswire Tickers DNLI Denali Therapeutics Announces Phase 1/2 Study Single Dose Healthy Volunteer Data with TAK-594/DNL593 (PTV:PGRN) and Progression to Enrolling Participants with FTD-GRN November 01, 2022 From Denali Therapeutics Inc. Via GlobeNewswire Tickers DNLI Denali Therapeutics Announces Closing of a $316 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares October 24, 2022 From Denali Therapeutics Inc. Via GlobeNewswire Tickers DNLI Denali Therapeutics Announces Pricing of $275 Million Public Offering of Common Stock October 19, 2022 From Denali Therapeutics Inc. Via GlobeNewswire Tickers DNLI Denali Therapeutics Announces Proposed Offering of Common Stock October 18, 2022 From Denali Therapeutics Inc. Via GlobeNewswire Tickers DNLI Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations October 03, 2022 From Denali Therapeutics Inc. Via GlobeNewswire Tickers BIIB DNLI Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.